About

Hemophilia A is a genetic disorder where the blood cannot clot properly due to a lack of factor VIII, leading to a serious risk of spontaneous and injury-related bleeding. Denecimig is a bispecific antibody designed to act like the missing factor VIII, bridging two key clotting proteins to help form a stable clot. By mimicking this natural clotting function, the drug could potentially provide consistent protection against bleeding episodes.